Skip to main content

Table 1 Demographics and medications for JDM patients and healthy controls

From: Serum protein biomarkers for juvenile dermatomyositis: a pilot study

  JDMa Controls (SomaScan®) Controls (ELISA)
Baselinen = 8 On Treatmentn = 7 Inactiven = 8b n = 12 n = 17
Age, yr, mean (stdv) 6.8 (2.7) 7.8 (2.7) 9.3 (1.9) 8.5 (1.7) 8.3 (2.3)
Gender
 Female, n 8 7 8 0 17
 Male, n 0 0 0 12 0
DAS Total,c mean (stdv) 11.0 (3.5) 4.6 (5.3) 0.6 (0.9)   
DAS Skin,c mean (stdv) 5.6 (1.7) 1.9 (2.0) 0.3 (0.5)   
DAS Muscle,c mean (stdv) 5.4 (3.3) 2.8 (3.4) 0.3 (0.6)   
Months between samples,mean (stdv)   7.4 (3.6) 20.8 (11.1)   
Drug, x = total patients on drug during studyd Months on drug at sample
mean (stdv)n = x
  
IV solumedrol, n = 7 n = 0 3.8 (1.0), n = 3 n = 0   
oral prednisone, n = 8 n = 0 6.6 (3.6), n = 7 20.8 (11.0), n = 3   
methotrexate, n = 7 n = 0 7.5 (3.9), n = 5 17.7 (0.9), n = 2   
cyclosporine, n = 2 n = 0 1.9, n = 1 n = 0   
mycophenolate mofetil, n = 5 n = 0 3.7 (3.1), n = 3 7.4 (6.8), n = 2   
hydroxychloroquine, n = 2 n = 0 4.9 (4.9), n = 2 27.2 (16.0), n = 2   
  1. a Same JDM patients were used for SomaScan® and ELISA assays except one missing datapoint for SomaScan® assay
  2. bone patient sample not available for SomaScan®
  3. c ranges for DAS: Skin (0–9) + Muscle (0–11) Total DAS (0–20)
  4. done patient had received IVIG 2.7 years prior to the inactive sample